
CLAIMS

What is claimed is:

1. A compound having the chemical structure of Formula I,



(Formula I)

or a salt, an ester, an amide, a carbamate, a carbonate, a ureido, a solvate, a hydrate, a tautomer or an isomer thereof,

wherein:

Ar is optionally substituted heteroaryl;

R^1 at each occurrence is independently selected from the group consisting of halogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, $-NO_2$, -CN, $-O-R^5$, $-N(R^5)-R^6$, $-C(X)-N(R^5)-R^6$, $-C(X)-R^7$, $-S(O)_2-N(R^5)-R^6$, $-S(O)_n-R^7$, $-O-C(X)-R^7$, $-C(X)-O-R^5$, $-C(NH)-N(R^8)-R^9$, $-N(R^5)-C(X)-R^7$, $-N(R^5)-S(O)_2-R^7$, $-N(R^5)-C(X)-N(R^5)-R^6$, and $-N(R^5)-S(O)_2-N(R^5)-R^6$;

m is 0, 1, 2, 3, 4 or 5;

n is 0, 1 or 2;

R^2 is hydrogen, lower alkyl or halogen;

L_2 is $-S(O)_2-$

R^3 is optionally substituted lower alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl or optionally substituted heteroaryl;

L_1 is selected from the group consisting of bond, $-X-C(R^{12}R^{13})-$, $-C(R^{12}R^{13})-N(R^{11})-$, $-N(R^{11})-C(R^{12}R^{13})-$, $-C(X)-N(R^{11})-$ and $-N(R^{11})-C(X)-$,

X is O

R^4 and each R^{11} are hydrogen;


R^5, R^6, R^8, and R^9 at each occurrence are independently selected from the group consisting of hydrogen, optionally substituted lower alkyl, optionally substituted C_{3-6} alkenyl, optionally substituted C_{3-6} alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl, or


R^8 and R^9 combine with the nitrogen to which they are attached to form a 5-7 membered optionally substituted nitrogen containing heterocycloalkyl or a 5 or 7 membered optionally substituted nitrogen containing heteroaryl;

R^7 at each occurrence is independently selected from the group consisting of optionally substituted lower alkyl, optionally substituted C_{3-6} alkenyl, optionally substituted C_{3-6} alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl;
R^{12} and R^{13} are hydrogen.

2. The compound of claim 1, wherein L_1 is -N(R^{11})-C(O)-.

3. The compound of claim 1, wherein L_1 is -C(X)-N(R^{11})-, -X-C($R^{12}R^{13}$)-, -C($R^{12}R^{13}$)-N(R^{11})-, or -N(R^{11})-C($R^{12}R^{13}$)-, and R^2 is hydrogen, fluoro, or chloro.

4. The compound of any one of claims 1-3, wherein 

is selected from the group consisting of 

wherein  indicates the attachment point of the Ar ring to L_1;

p is 0, 1, 2 or 3;
R^{16} at each occurrence is independently selected from the group consisting of -OH, -NH_2, -CN, -NO_2, -C(O)-OH, -$S(O)_2$-NH_2, -C(O)-NH_2, -O-R^{17}, -S-R^{17}, -N(R^{19})-R^{17}, -N(R^{19})-C(O)-R^{17}, -N(R^{19})$S(O)_2$-R^{17}, -$S(O)_2$-R^{17}, -C(O)-R^{17}, -C(O)-O-R^{17}, -C(O)-N(R^{19})-R^{17}, -$S(O)_2$-N(R^{19})-R^{17}, halogen, lower alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, wherein lower alkyl is optionally substituted with one or more substituents selected from the group consisting of fluoro, lower alkoxy, fluoro substituted lower alkoxy, lower alkylthio, fluoro substituted lower alkylthio, mono-alkylamino, di-alkylamino, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, wherein cycloalkyl, heterocycloalkyl, aryl, and heteroaryl as R^{16}, or as substituents of lower alkyl, are optionally substituted with one or more substituents selected from the group consisting of -OH, -NH_2, -CN, -NO_2, -C(O)-OH, -$S(O)_2$-NH_2, -C(O)-NH_2, -O-R^{18}, -S-R^{18}, -N(R^{19})-R^{18}, -N(R^{19})-C(O)-R^{18}, -N(R^{19})-$S(O)_2$-R^{18}, -$S(O)_2$-R^{18}, -C(O)-R^{18}, -C(O)-O-R^{18}, -C(O)-N(R^{19})-R^{18}, -$S(O)_2$-N(R^{19})-R^{18}, halogen, lower alkyl, fluoro substituted lower alkyl, and cycloalkylamino;
R^{17} at each occurrence is independently selected from the group consisting of lower alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, wherein lower alkyl is optionally substituted with one or more

substituents selected from the group consisting of fluoro, lower alkoxy, fluoro substituted lower alkoxy, lower alkylthio, fluoro substituted lower alkylthio, mono-alkylamino, di-alkylamino, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, wherein cycloalkyl, heterocycloalkyl, aryl, and heteroaryl as R^{17} or as substituents of lower alkyl are optionally substituted with one or more substituents selected from the group consisting of -OH, $-NH_2$, -CN, $-NO_2$, -C(O)-OH, $-S(O)_2-NH_2$, $-C(O)-NH_2$, $-O-R^{18}$, $-S-R^{18}$, $-N(R^{19})-R^{18}$, $-N(R^{19})-C(O)-R^{18}$, $-N(R^{19})-S(O)_2-R^{18}$, $-S(O)_2-R^{18}$, $-C(O)-R^{18}$, $-C(O)-O-R^{18}$, $-C(O)-N(R^{19})-R^{18}$, $-S(O)_2-N(R^{19})-R^{18}$, halogen, lower alkyl, fluoro substituted lower alkyl, and cycloalkylamino;
R^{18} at each occurrence is independently selected from the group consisting of lower alkyl, heterocycloalkyl and heteroaryl, wherein lower alkyl is optionally substituted with one or more substituents selected from the group consisting of fluoro, lower alkoxy, fluoro substituted lower alkoxy, lower alkylthio, fluoro substituted lower alkylthio, mono-alkylamino, di-alkylamino, and cycloalkylamino; and
R^{19} at each occurrence is independently hydrogen or lower alkyl, wherein lower alkyl is optionally substituted with one or more substituents selected from the group consisting of fluoro, lower alkoxy, fluoro substituted lower alkoxy, lower alkylthio, and fluoro substituted lower alkylthio.


5. A composition comprising a pharmaceutically acceptable carrier and a compound according to any one of claims 1-4.

6. A kit comprising a compound according to any one of claims 1-4 or a composition according to claim 5 and written instructions for use.

7. A compound of any one of claims 1-4 or a composition of claim 5 for use in treating a subject suffering from or at risk of a Raf mediated disease or condition.

8. Use of a compound of any one of claims 1-4 or a composition of claim 5 for the manufacture of a medicament for treating a subject suffering from or at risk of a Raf mediated disease or condition.

9. A compound of formula (Ia):



(Ia)

or a pharmaceutically acceptable salt thereof,
wherein:
L_1 is a bond or -N(H)C(O)-;
each R^1 is optionally substituted lower alkyl or optionally substituted heteroaryl;

R^2 is hydrogen or halogen;
R^4 is hydrogen;
R^3 is optionally substituted lower alkyl or optionally substituted aryl;
m is 0, 1, 2, or 3; and
Ar is a monocyclic heteroaryl containing 5 to 6 atoms wherein at least one atom is nitrogen.

10. The compound of claim **9**, wherein R^2 is hydrogen.

11. The compound of claim **9**, wherein R^2 is halogen.

12. The compound of claim **9**, wherein R^3 is optionally substituted phenyl.

13. The compound of claim **9**, wherein R^3 is phenyl substituted with one or more substituents selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, fluoro substituted lower alkoxy, lower alkylthio, and fluoro substituted lower alkylthio.


14. The compound of claim **9,** wherein R^3 is phenyl substituted with one or more fluoro.

15. The compound of claim **9**, wherein one of the R^1 substituents is optionally substituted lower alkyl containing 1-4 carbon atoms.

16. The compound of claim **9**, wherein one of the R^1 substituents is optionally substituted heteroaryl.

17. A pharmaceutical composition comprising a compound of claim **9** and a pharmaceutically acceptable carrier or excipient.

18. A compound of formula (Ia):



(Ia)

or a pharmaceutically acceptable salt thereof,
wherein:
L_1 is a bond;
each R^1 is optionally substituted lower alkyl or optionally substituted heteroaryl;
R^2 is hydrogen or halogen;
R^4 is hydrogen;
R^3 is optionally substituted lower alkyl or optionally substituted aryl;
m is 0, 1, 2, 3, 4, or 5; and
Ar is a monocyclic heteroaryl containing 5 to 6 atoms wherein at least one atom is nitrogen.

19. The compound of claim **18**, wherein R^2 is hydrogen.

20. The compound of claim **18**, wherein R^2 is halogen.

21. The compound of claim **18**, wherein R^3 is optionally substituted phenyl.

22. The compound of claim **18**, wherein R^3 is phenyl substituted with one or more substituents selected from the group consisting of fluoro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, fluoro substituted lower alkoxy, lower alkylthio, and fluoro substituted lower alkylthio.

23. The compound of claim **18**, wherein R^3 is phenyl substituted with one or more fluoro.

24. The compound of claim **18**, wherein one of the R^1 substituents is optionally substituted lower alkyl containing 1-4 carbon atoms.

25. The compound of claim **18**, wherein one of the R^1 substituents is optionally substituted heteroaryl.

26. A pharmaceutical composition comprising a compound of claim **18** and a pharmaceutically acceptable carrier or excipient.